Justine Leclerc

Justine Leclerc

Auto-generated profile, based on publicly available information

Justine Leclerc

Université Côte d'Azur, Nice, France; Inserm U1065, Biology and Pathologies of Mélanocytes, Team 1, Centre Méditerranéen de Médecine Moléculaire, Nice, France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2017 in Genes & Development
Verified
Journal Article
Open access
PDF file
CPCharlotte Pandiani
Charlotte Pandiani
GBGuillaume E. Béranger
Guillaume E. Béranger
JLJustine Leclerc
Justine Leclerc
RBRobert Ballotti
Robert Ballotti
CBCorine Bertolotto
Corine Bertolotto
Cutaneous melanoma (CM) and uveal melanoma (UM) derive from cutaneous and uveal melanocytes that share the same embryonic origin and display the same cellular function. However, the etiopathogenesis and biological behaviors of these melanomas are very different. CM and UM display distinct landscapes of genetic alterations and show different metastatic routes and tropisms. Hence, therapeutic improvements achieved in the last few years for the treatment of CM have failed to ameliorate the clinical outcomes of patients with UM. The scope of this review is to discuss the differences in tumorigenic processes (etiologic factors and genetic alterations) and tumor biology (gene expression and signaling pathways) between CM and UM. We develop hypotheses to explain these differences, which might provide important clues for research avenues and the identification of actionable vulnerabilities suitable for the development of new therapeutic strategies for metastatic UM.

25 September 2018 in Oncogene
Verified
Journal Article
Closed access
PDF file
JLJustine Leclerc
Justine Leclerc
DGDavid Garandeau
David Garandeau
CPCharlotte Pandiani
Charlotte Pandiani
CGCéline Gaudel
Céline Gaudel
KBKarine Bille
Karine Bille
CBCorine Bertolotto
Corine Bertolotto

14 March 2017 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
CBCaroline Bonet
Caroline Bonet
FLFlavie Luciani
Flavie Luciani
JOJean-François Ottavi
Jean-François Ottavi
JLJustine Leclerc
Justine Leclerc
FJFanélie-Marie Jouenne
Fanélie-Marie Jouenne
CBCorine Bertolotto
Corine Bertolotto
Background:MITF encodes an oncogenic lineage-specific transcription factor in which a germline mutation (MITFE318K) was identified in human patients predisposed to both nevus formation and, among other tumor types, melanoma. The molecular mechanisms underlying the oncogenic activity of MITFE318K remained uncharacterized. Methods: Here, we compared the SUMOylation status of endogenous MITF by proximity ligation assay in melanocytes isolated from wild-type (n = 3) or E318K (n = 4) MITF donors. We also used a newly generated MitfE318K knock-in (KI) mouse model to assess the role of MitfE318K (n = 7 to 13 mice per group) in tumor development in vivo and performed transcriptomic analysis of the tumors to identify the molecular mechanisms. Finally, using immortalized or normal melanocytes (wild-type or E318K MITF, n = 2 per group), we assessed the role of MITFE318K on the induction of senescence mediated by BRAFV600E. All statistical tests were two-sided. Results: We demonstrated a decrease in endogenous MITF SUMOylation in melanocytes from MITFE318K patients (mean of cells with hypoSUMOylated MITF, MITFE318K vs MITFWT, 94% vs 44%, difference = 50%, 95% CI = 21.8% to 67.2%, P = .004). The MitfE318K mice were slightly hypopigmented (mean melanin content MitfWT vs MitfE318K/+, 0.54 arbitrary units [AU] vs 0.36 AU, difference = −0.18, 95% CI = −0.36 to −0.007, P = .04). We provided genetic evidence that MitfE318K enhances BRafV600E-induced nevus formation in vivo (mean nevus number for MitfE318K, BRafV600E vs MitfWT, BRafV600E, 68 vs 44, difference = 24, 95% CI = 9.1 to 38.9, P = .006). Importantly, although MitfE318K was not sufficient to cooperate with BRafV600E alone in promoting metastatic melanoma, it accelerated tumor formation on a BRafV600E, Pten-deficient background (median survival, MitfE318K/+ = 42 days, 95% CI = 31 to 46 vs MitfWT = 51 days, 95% CI = 50 to 55, P < .001). Transcriptome analysis suggested a decrease in senescence in tumors from MitfE318K mice. We confirmed this hypothesis by in vitro experiments, demonstrating that MitfE318K impaired the ability of human melanocytes to undergo BRAFV600E-induced senescence. Conclusions: We characterized the functions of melanoma-associated MITFE318K mutations. Our results demonstrate that MITFE318K reduces the program of senescence to potentially favor melanoma progression in vivo.

1 February 2019 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
DGDavid Garandeau
David Garandeau
JNJustine Noujarède
Justine Noujarède
JLJustine Leclerc
Justine Leclerc
CICaroline Imbert
Caroline Imbert
VGVirginie Garcia
Virginie Garcia
NANathalie Andrieu-Abadie
Nathalie Andrieu-Abadie
BRAF inhibitors (BRAFi) are used to treat patients with melanoma harboring the V600E mutation. However, resistance to BRAFi is inevitable. Here, we identified sphingosine 1-phosphate (S1P) receptors as regulators of BRAFV600E-mutant melanoma cell-autonomous resistance to BRAFi. Moreover, our results reveal a distinct sphingolipid profile, that is, a tendency for increased very long-chain ceramide species, in the plasma of patients with melanoma who achieve a response to BRAFi therapy as compared with patients with progressive disease. Treatment with BRAFi resulted in a strong decrease in S1PR1/3 expression in sensitive but not in resistant cells. Genetic and pharmacologic interventions, that increase ceramide/S1P ratio, downregulated S1PR expression and blocked BRAFi-resistant melanoma cell growth. This effect was associated with a decreased expression of MITF and Bcl-2. Moreover, the BH3 mimetic ABT-737 improved the antitumor activity of approaches targeting S1P-metabolizing enzymes in BRAFi-resistant melanoma cells. Collectively, our findings indicate that targeting the S1P/S1PR axis could provide effective therapeutic options for patients with melanoma who relapse after BRAFi therapy.

21 August 2017 in Oncogene
Verified
Journal Article
Closed access
JLJ Leclerc
J Leclerc
RBR Ballotti
R Ballotti
CBCorine Bertolotto
Corine Bertolotto

1 November 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CGCéline Gaudel
Céline Gaudel
FSFrédéric Soysouvanh
Frédéric Soysouvanh
JLJustine Leclerc
Justine Leclerc
KBKarine Bille
Karine Bille
CHChrystel Husser
Chrystel Husser
RBRobert Ballotti
Robert Ballotti